Catalent Inc
Change company Symbol lookup
Select an option...
CTLT Catalent Inc
TFPM Triple Flag Precious Metals Corp
SCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027
GMBL Esports Entertainment Group Inc
CFRX ContraFect Corp
AAL American Airlines Group Inc
NVDA NVIDIA Corp
AMD Advanced Micro Devices Inc
QQQ Invesco QQQ Trust
AAPL Apple Inc
Go

Health Care : Pharmaceuticals | Mid Cap Blend
Company profile

Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Its Biologics segment provides development and manufacturing for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene therapies. Its Softgel and Oral Technologies segment provide formulation, development, and manufacturing services for soft capsules, as well as large-scale manufacturing of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. Its Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for, drugs, biologics and clinical trials.

Closing Price
$52.27
Day's Change
2.11 (4.21%)
Bid
--
Ask
--
B/A Size
--
Day's High
52.32
Day's Low
50.71
Volume
(Above Average)
Volume:
2,810,252

10-day average volume:
2,496,045
2,810,252

Display:

Providers:

UpdateCancel
6 providers
January 20, 2023
Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it will release...(BusinessWire)

January 17, 2023
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America. Mr. Zayas...(BusinessWire)

January 09, 2023
Avantor(R) and Catalent Enter into Multi-Year Supply and Services Agreement

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it has entered into a multi-year supply...(PR Newswire)

January 05, 2023
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the...(BusinessWire)

January 03, 2023
Catalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its...(BusinessWire)

December 19, 2022
Catalent Announces Changes to its Board of Directors

--Executive Chair John Chiminski and Directors Rolf Classon and Peter Zippelius to Retire Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better...(BusinessWire)

November 08, 2022
Catalent, Inc. to Present at the Stephens Annual Investment Conference

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its...(BusinessWire)

November 03, 2022
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis' Biologics Pipeline

Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announced a new license agreement under which Catalent's Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with lead antibody and/or...(BusinessWire)

November 01, 2022
Catalent, Inc. Reports First Quarter Fiscal 2023 Results

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.